The global Fill-finish Pharmaceutical Contract Manufacturing Market size is expected to reach USD 14.0 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 6.1% from 2022 to 2030. Increasing demand for drugs across the global market and the advantage of the reduction in the overall investment for developing drugs with contract manufacturing are the key factors driving the growth of the market. Contract fill-and-finish services are one of the most commonly outsourced services presently. Almost all pharmaceutical and biotech firms outsource at least some of their fill-and-finish requirements.
Unpredicted demand, second source policies, and better
matching scale with need are all factors to consider when utilizing a CMO's
capacity. Highly specialized capabilities like prefilled syringes,
lyophilization, and cartridges, as well as novel therapeutics, necessitate
specialized manufacturing that is more cost-effective to outsource. Firms with
in-house aseptic fill/finish capacity outsource 39% of their fill and finish
requirements, according to contract pharma. Furthermore, filling accounts for
59% of the market, while lyophilization accounts for 24%.
However, the COVID-19 pandemic spurred the development
of COVID-19 vaccines, antibody therapy, antiviral drugs, and a variety of other
related pharmaceutical products. The pandemic severely impacted countries such
as Brazil, India, the U.S., and major European countries, increasing demand for
biopharmaceutical products and, as a result, drug
production. Vaccines and biologics require special
manufacturing and fill-finish equipment and procedures to ensure product
quality and safety, necessitating advanced analytical competencies and
adaptable aseptic fill-finish technologies. This resulted in the positive
impact of covid-19 on the market.
Related Press Release@ Fill-finish Pharmaceutical Contract Manufacturing Market Report
Fill-finish Pharmaceutical
Contract Manufacturing Market Report Highlights
- The large molecules segment dominated the market with a revenue
share of 67.3% in 2021. Rising investment by pharmaceutical companies in
R&D for large molecules and biosimilar would drive market growth
- The vials segment accounted for the largest revenue share of 52.9%
in 2021. They are the most versatile and easy-to-use dosage form. It is
observed that the vial filling reduces the product loss and maximizes
yield
- Based on end-user, the biopharmaceutical companies segment
accounted for the largest share of 54.9% in 2021. The increased demand for
biopharmaceutical drugs, as well as funding for the biotech sector drive
market growth
- Asia Pacific led the market in 2021 and is projected to witness the
fastest CAGR of 6.3% during the forecast years due to the rising number of
CMOs expanding in the region and a huge number of fill-finish facilities
being constructed. For instance, Thermo Fisher would increase sterile
filling capacity with a new facility in Singapore. The facility would then
initially provide a high-speed sterilized line approved for live
virus having to fill first large-scale expertise in Singapore followed by
an additional feature for standard fill/finish
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment